UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 145

Sortiert nach

A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer

Breast cancer research and treatment, 2024-01, Vol.203 (2), p.197-204

2024

Volltextzugriff (PDF)

Molecular Pathways and Mechanisms of HER2 in Cancer Therapy

Clinical cancer research, 2023-07, Vol.29 (13), p.2351-2361

2023

Volltextzugriff (PDF)

Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1091-1091

2023

Volltextzugriff (PDF)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

Cell reports (Cambridge), 2022-09, Vol.40 (10), p.111338-111338, Article 111338

2022

Volltextzugriff (PDF)

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate, SGN-CD70A, in patient-derived xenograft models

European journal of cancer (1990), 2022-09, Vol.173, p.S17

2022

Volltextzugriff (PDF)

Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions

Cancer research (Chicago, Ill.), 2022-08, Vol.82 (16), p.2811-2820

Moasser, Mark M.

2022

Volltextzugriff (PDF)

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies

Cancer research communications, 2022-07, Vol.2 (7), p.570-576

2022

Volltextzugriff (PDF)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers

Cell reports (Cambridge), 2022-02, Vol.38 (5), p.110291-110291, Article 110291

2022

Volltextzugriff (PDF)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

Cell reports (Cambridge), 2022-02, Vol.38 (5), p.110285-110285, Article 110285

2022

Volltextzugriff (PDF)

Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain

Molecular cancer research, 2021-06, Vol.19 (6), p.957-967

2021

Volltextzugriff (PDF)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers

Scientific reports, 2021-04, Vol.11 (1), p.9091-11, Article 9091

2021

Volltextzugriff (PDF)

Expression and purification of active human kinases using Pichia pastoris as a general-purpose host

Protein expression and purification, 2021-03, Vol.179, p.105780-105780, Article 105780

2021

Volltextzugriff (PDF)

Abstract PS2-19: Circulating tumor cell (CTC) enumeration in a phase II trial of pazopanib in addition to endocrine therapy in patients with hormone resistant advanced breast cancer (ABC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS2-19-PS2-19

2021

Volltextzugriff (PDF)

Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A

Biochemical pharmacology, 2021-01, Vol.183, p.114317-114317, Article 114317

2021

Volltextzugriff (PDF)

Loss of CDCP1 triggers FAK activation in detached prostate cancer cells

American journal of clinical and experimental urology, 2021-01, Vol.9 (4), p.350-366

2021

Volltextzugriff (PDF)

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1076-1076

2020

Volltextzugriff (PDF)

HER family in cancer progression: From discovery to 2020 and beyond

Advances in cancer research, 2020, Vol.147, p.109-160

2020

Volltextzugriff (PDF)

Abstract B023: A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.B023-B023

2019

Volltextzugriff (PDF)

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities

Nature cell biology, 2019-06, Vol.21 (6), p.778

2019

Volltextzugriff (PDF)

A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src

Cell reports (Cambridge), 2018-10, Vol.25 (2), p.449-463.e4

2018

Volltextzugriff (PDF)

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13), p.3645-3658

2018

Volltextzugriff (PDF)

Regulation of inside-out β1-integrin activation by CDCP1

Oncogene, 2018-05, Vol.37 (21), p.2817-2836

2018

Volltextzugriff (PDF)

Targeting HER2 by Combination Therapies

Journal of clinical oncology, 2018-03, Vol.36 (8), p.808-811

2018

Volltextzugriff (PDF)

CD318 is a ligand for CD6

Proceedings of the National Academy of Sciences - PNAS, 2017-08, Vol.114 (33), p.E6912-E6921

2017

Volltextzugriff (PDF)

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(138)

Publikationsform

Sprache

Englisch
(145)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(30)
Cancer Research
(15)
Clinical Cancer Research
(12)
Oncogene
(11)
Breast Cancer Research And Treatment
(8)
Cell Cycle
(5)
Cell Reports
(4)
Biochemical Journal
(3)
European Journal Of Cancer
(3)
Molecular Cancer Therapeutics
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer

Molecular Pathways and Mechanisms of HER2 in Cancer Therapy

Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC)

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF V600E colorectal tumors

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate, SGN-CD70A, in patient-derived xenograft models

Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers

Expression and purification of active human kinases using Pichia pastoris as a general-purpose host

Abstract PS2-19: Circulating tumor cell (CTC) enumeration in a phase II trial of pazopanib in addition to endocrine therapy in patients with hormone resistant advanced breast cancer (ABC)

Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A

Loss of CDCP1 triggers FAK activation in detached prostate cancer cells

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression

HER family in cancer progression: From discovery to 2020 and beyond

Abstract B023: A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities

A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3

Regulation of inside-out β1-integrin activation by CDCP1

Targeting HER2 by Combination Therapies

CD318 is a ligand for CD6

Suchergebnisse filtern